文献速递淋巴瘤

免疫化疗方案对IELSG37试验中原发性纵隔B细胞淋巴瘤患者结局的影响

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.
PubMed 文献 · Blood · 2025-01-01

IELSG37试验纳入545例原发性纵隔B细胞淋巴瘤患者,证实完全代谢缓解(Deauville评分1–3)者可省略巩固放疗。本报告评估按当地实践选择的不同前线利妥昔单抗联合多柔比星为基础免疫化疗方案的结局,R-CHOP21组Deauville评分5的比例显著更高(23.8% vs 其他方案平均8.2%;P < .001),但无进展生存和总生存差异未达统计学显著。

要点

  • R-CHOP21组Deauville评分5比例显著高于其他方案(23.8% vs 8.2%平均;P < .001)。
  • R-CHOP21组额外非计划治疗有增多趋势(53.2% vs 46.9%;P = .30),未达统计学显著。
  • Deauville评分5患者更多接受额外治疗(96% vs 41%;P < .001)且结局显著更差。

核心结论

  • R-CHOP21可能增加额外治疗风险,作为原发性纵隔B细胞淋巴瘤前线治疗可能不可取。
  • R-CHOP21与更强方案间无进展生存和总生存差异未达统计学显著。

研究设计与样本

  • IELSG37试验纳入545例原发性纵隔B细胞淋巴瘤患者,本报告评估按当地实践选择的不同前线利妥昔单抗联合多柔比星为基础免疫化疗方案的结局。
  • 试验注册号为NCT01599559。

主要发现

  • R-CHOP21组Deauville评分5比例显著高于其他方案(23.8% vs 8.2%平均;P < .001)。
  • R-CHOP21组额外非计划治疗有增多趋势(53.2% vs 46.9%;P = .30)。
  • 校正年龄、性别、国际预后指数评分和体能状态后的多项逻辑回归分析证实了应答不佳风险增加。
  • R-CHOP21与代谢肿瘤体积缩小幅度更小和最大标准化摄取值下降更不明显相关。
  • Deauville评分5患者更常在诱导免疫化疗后接受额外治疗(放疗和/或挽救化疗联合或不联合自体巩固)(96% vs 41%;P < .001)且结局显著更差。

关键数值与推荐

  • 完全代谢缓解按Lugano分类定义为Deauville评分1–3。
  • R-CHOP21为利妥昔单抗、环磷酰胺、多柔比星、长春新碱、泼尼松龙每21天给药。

临床怎么用

  • 作者认为R-CHOP21可能增加额外治疗风险,作为原发性纵隔B细胞淋巴瘤前线治疗可能不可取。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The IELSG37 trial enrolled 545 patients with primary mediastinal B-cell lymphoma (PMBCL) and demonstrated that consolidation radiotherapy (RT) can be omitted in patients with complete metabolic response, defined by the Lugano classification as Deauville score (DS) 1 to 3. This report evaluates outcomes after different frontline rituximab- and doxorubicin-based immunochemotherapy regimens chosen according to local practice. Patients treated with R-CHOP21 (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone, administered every 21 days) showed a significantly higher percentage of DS 5 than those on other regimens (23.8% vs 8.2% average; P < .001) and a trend toward additional unplanned treatments (53.2% vs 46.9%; P = .30). The increased risk of poor response was confirmed in a multinomial logistic regression analysis adjusted for age, sex, international prognostic index score, and performance status. R-CHOP21 was also associated with smaller reductions in metabolic tumor volume and less pronounced decreases in maximum standardized uptake value. Patients with DS 5 more often received additional treatment (RT and/or salvage chemotherapy with or without autologous consolidation) after induction immunochemotherapy (96% vs 41%; P < .001) and experienced significantly poorer outcomes. Although differences in progression-free and overall survival between R-CHOP21 and more aggressive regimens were not statistically significant, R-CHOP21 may increase the risk of additional treatments and may be inadvisable as frontline therapy for PMBCL. This trial was registered at www.clinicaltrials.gov as #NCT01599559.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Zucca E, Ceriani L, Ciccone G, et al. Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial. Blood. 2025. PMID: 40939190. doi:10.1182/blood.2025028823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。